Drug Discovery World

JULY 5, 2024

Amgen has reported positive topline results from its randomised, double-blind, multicentre, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of its treatment for Immunoglobulin G4-related disease (IgG4-RD).

Treatment 147

Treatment Medical Schools Trials Clinical Trials 147

Drug Discovery World

SEPTEMBER 15, 2022

A new combination therapy could represent a significant advancement in the treatment of metastatic colorectal cancer. Findings from the SUNLIGHT trial have revealed that the combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in overall survival compared to trifluridine/tipiracil alone.

Trials 130

Trials Treatment Clinical Trials Hospitals 130

Drug Discovery World

DECEMBER 16, 2022

Jannsen has revealed clinical trial results for its pipeline of products to treat multiple myeloma and leukaemia. . Along with positive Phase II trial data for talquetamab , the company presented promising findings on the long-term results of daratumumab in newly diagnosed, transplant-ineligible multiple myeloma patients. .

Trials 130

Trials Treatment Clinical Trials Therapies 130

Drug Discovery World

JANUARY 18, 2024

The results, together with the data from the recent LPS human challenge trial, further support the strategic expansion of the Phase II ready POLB 001 to treat and prevent cancer immunotherapy-induced CRS. Reductions were seen in all serum proinflammatory cytokines tested.

Treatment 162

Treatment Immune Response Clinical Trials Therapies 162

Drug Discovery World

JANUARY 31, 2024

Breye Therapeutics, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, has started a Phase Ib/IIa clinical trial to investigate danegaptide, following oral administration, in patients suffering from diabetic macular oedema (DMO).

Treatment 130

Treatment Clinical Trials Pharmacokinetics Trials 130

Drug Discovery World

MARCH 1, 2023

The new Liverpool Clinical Research Facility (CRF) unit has opened at the new Royal Liverpool University Hospital thanks to £5.3m ($6.4m) funding from the National Institute for Health Research (NIHR). The CRF will explore new treatments and vaccines for a range of diseases prevalent in Liverpool’s communities.

Clinical Trials 130

Clinical Trials Trials Hospitals Clinical Research 130

Drug Discovery World

JANUARY 17, 2023

Genoscience Pharma, a clinical-stage biotech company developing lysosomotropic drug candidates for the treatment of cancer, fibrosis and auto-immune diseases through autophagy modulation has launched the ABE-LIVER study, along with trial sponsor Grenoble University Hospital. . The trial . The primary criteria is PFS.

Clinical Trials 130

Clinical Trials Trials Drug Development Hospitals 130

Drug Discovery World

OCTOBER 2, 2023

The European Commission (EC) has approved INAQOVI (oral decitabine and cedazuridine) as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy.

Treatment 130

Treatment Pharmacokinetics Clinical Trials Licensing 130

Drug Discovery World

MAY 17, 2024

Deepika Khedekar , Associate Centralized Clinical Trial Lead at IQVIA Inc, looks at the challenges of utilising artificial intelligence (AI) in oncology clinical research. MIT research 4 tells us a hard truth: about 95% of these trials fall short, leaving behind a trail of broken hopes for cancer patients each year.

Trials 147

Trials Clinical Trials Treatment Research 147

SCIENMAG: Medicine & Health

SEPTEMBER 22, 2023

A clinical trial has launched to test whether early intensive immune modulation for hospitalized COVID-19 patients with relatively mild illness is beneficial.

Clinical Trials 52

Clinical Trials Hospitals Trials Treatment 52

Drug Discovery World

APRIL 26, 2024

A clinical trial of a personalised mRNA cancer vaccine for melanoma patients has been launched in the UK. The post “Game-changing” personalised cancer vaccine enters UK clinical trials appeared first on Drug Discovery World (DDW). in the combination arm and 62.2%

Clinical Trials 130

Clinical Trials Vaccine Trials Immune Response 130

Drug Discovery World

OCTOBER 31, 2023

UK regulatory authorities have approved the first trial of a gene therapy for young children with Hunter syndrome. The post First gene therapy trial for Hunter syndrome opens in Manchester, UK appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies Trials Clinical Trials Hospitals 130

Drug Discovery World

JANUARY 30, 2023

The primary objectives of MOVE were to evaluate the efficacy of palovarotene in reducing new HO volume, as assessed using whole-body computed tomography. “There is a significant need for a treatment specifically developed to help manage the progression of this disease.

Treatment 130

Treatment Disease Clinical Trials Trials 130

Drug Discovery World

APRIL 12, 2023

Evecxia Therapeutics has reported favourable safety, tolerability, pharmacokinetic, and pharmacodynamic data from a Phase I trial of EVX-101 in healthy volunteers treated with escitalopram. Details of the trial In EVX-101, the 5-HTP dose is fixed at 250mg, while variable levels of carbidopa control 5-HTP plasma exposure levels.

Trials 130

Trials Clinical Pharmacology Medical Schools Pharmacokinetics 130

Drug Discovery World

JULY 5, 2024

The Division of Clinical Neuroscience at Oslo University Hospital (OUS) and the Swedish drug development company TikoMed have signed a research collaboration agreement focused on amyotrophic lateral sclerosis (ALS).

Drug Research 204

Drug Research Research Hospitals Drugs 204

Drug Discovery World

APRIL 10, 2023

RESP-X, Infex Therapeutics’ anti-virulence therapy to treat Pseudomonas aeruginosa (Pa) infections in non-cystic fibrosis bronchiectasis (NCFB) patients, has shown a promising interim safety and tolerability profile in its ongoing first-in-human Phase I clinical trial.

Clinical Trials 130

Clinical Trials Trials Laboratories Clinical Research 130

Drug Discovery World

APRIL 5, 2023

CureSearch for Children’s Cancer, a national non-profit with a mission to end childhood cancer by driving targeted and innovative research in an accelerated time frame, will fund a Phase I clinical trial to bring new therapies to paediatric brain cancer patients, including those with limited or no treatment options.

Clinical Trials 130

Clinical Trials Trials Therapies Treatment 130

Drug Discovery World

FEBRUARY 6, 2024

The first UK patients have received an mRNA cancer therapy – mRNA-4359 – as part of a Phase I/II clinical trial investigating its potential for treating melanoma, lung cancer and other solid tumour cancers. The trial is sponsored by Moderna through the Moderna-UK Strategic Partnership.

Therapies 278

Therapies Clinical Trials Trials Government 278

Drug Discovery World

SEPTEMBER 8, 2022

The data will be used to explore the efficacy of BBT-877 and to demonstrate the value that Brainomix AI-powered imaging biomarkers offer as new endpoints for future IPF clinical trials. The post Phase II IPF trial to benefit from AI imaging appeared first on Drug Discovery World (DDW).

Trials 130

Trials Clinical Trials Disease Hospitals 130

Drug Discovery World

JULY 11, 2022

Pharmaceutical company Novo Nordisk has announced positive results for its prophylactic treatment targeting people living with haemophilia A or B with inhibitors. . The company’s concizumab treatment is an anti-tissue factor pathway inhibitor (TFPI)? The treatment of haemophilia is complex and no one treatment fits all, ” ?

Treatment 130

Treatment Pharmaceutical Companies Hospitals Trials 130

Drug Discovery World

SEPTEMBER 13, 2022

Ayala Pharmaceuticals has revealed positive interim results from its ongoing RINGSIDE Pivotal Phase II and III clinical trial into gamma-secretase inhibitor AL102 in desmoid tumours. The post New treatment hope for patients with rare tumours appeared first on Drug Discovery World (DDW).

Treatment 130

Treatment FDA Approval Clinical Trials Hospitals 130

Drug Discovery World

AUGUST 23, 2022

The European Medicines Agency (EMA) has granted a Marketing Authorisation Application (MAA) for a combination treatment targeting adults with acute myeloid leukaemia (AML) who are not candidates for standard induction chemotherapy. . Poster presented at EHA Annual Meeting, Vienna, Austria June 9 – 12, 2022. Abstract P573.

Treatment 130

Treatment Pharmacokinetics Clinical Trials DNA 130

Drug Discovery World

JUNE 4, 2024

Phase II trial results have shown the superiority of immunotherapy pembrolizumab over chemotherapy when given before bowel cancer surgery. They are interim results from the NEOPRISM-CRC Phase II clinical trial in patients with stage two or stage three MMR deficient/MSI-High bowel cancer. The median cancer-free period was 9.7

Trials 130

Trials Hospitals Clinical Trials Treatment 130

Drug Discovery World

OCTOBER 10, 2022

A new clinical trial, led by the University of Glasgow and NHS Greater Glasgow and Clyde (NHSGGC), hopes to improve treatment options for patients with Crohn’s disease. . Unfortunately, no currently available treatment provides an effective solution for all patients. Official comments.

Disease 130

Disease Treatment Hospitals Therapies 130

Drug Discovery World

JUNE 19, 2024

KYV-101, a fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, has been used to treat a 69-year-old patient suffering from treatment-refractory stiff-person syndrome (SPS). The treatment was well tolerated and led to a significant improvement in walking distance and 40% reduction in GABAergic medications. “It

Therapies 246

Therapies Disease Hospitals Treatment 246

Drug Discovery World

FEBRUARY 9, 2023

Launched in 2020, the Oxford-based business hopes the designation will “open regulatory discussions, supplement funding, increase the viability of drug development and enable quick access to market a treatment.” SynaptixBio CEO and co-founder Dr Dan Williams said the designation was a “monumental step forward” in its bid to treat the disease.

Treatment 130

Treatment Disease Clinical Trials FDA 130

Drug Discovery World

JULY 12, 2023

Diuretic-resistance is widespread with nearly half of these patients leaving hospital with persistent congestion, and one in four readmitted within 30 days of discharge. Following four weeks of treatment, there is a three-month safety follow-up period.

Trials 130

Trials Disease Therapies Treatment 130

Drug Discovery World

OCTOBER 2, 2024

The drug entered Phase II clinical trials in July 2024, which are expected to complete in 2025. As we progress though our Phase IIa trial of ETD001, this RPD designation will further support our mission to advance this novel approach for treating pwCF with the highest unmet medical need, as rapidly as possible.”

Disease 147

Disease FDA Drugs Clinical Trials 147

Drug Discovery World

AUGUST 12, 2024

Phase II trial results for Levicept’s LEVI-04, a novel and first in class neurotrophin-3 (NT-3) inhibitor, have shown that the drug was highly effective and well tolerated. It was led by Professor Philip Conaghan from the University of Leeds and Leeds Teaching Hospitals NHS Trust, UK.

Trials 147

Trials Hospitals Regulations Treatment 147

KIF1A

MAY 29, 2024

Fortunately, Sloane does not currently have epilepsy, and Megan hopes this treatment will prevent it’s onset as her disease progresses. On the day of the treatment, they checked into the hospital where Sloane was administered sedation medication. The post Sloane’s 1st ASO treatment appeared first on KIF1A.

Treatment 52

Treatment Doctors Hospitals Therapies 52

Drug Discovery World

SEPTEMBER 20, 2024

The clinical trial results and case studies were presented in posters and a company-sponsored symposium at the 40 th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Disease 147

Disease Therapies Clinical Trials Trials 147

Advarra

OCTOBER 1, 2024

Managing clinical trial budgets efficiently is necessary for the success and sustainability of clinical research sites. Effective budget management not only ensures trials are financially viable but also maximizes return on investment (ROI). the impact and value of the data produced).

Clinical Trials 52

Clinical Trials Trials Compliance Laboratories 52

Drug Discovery World

JUNE 27, 2024

Novo Nordisk has announced results from the Phase III FRONTIER2 trial of 254 adults and adolescents aged 12 years and over with haemophilia A, with and without inhibitors. The trial assessed both once-weekly and once-monthly prophylactic treatment with the investigational treatment Mim8. for once-monthly treatment.

FDA Approval 147

FDA Approval Trials Treatment Hospitals 147

Drug Target Review

JANUARY 23, 2024

What innovative approaches and technologies are anticipated to reshape immuno-oncology treatments in 2024? Immuno-oncology, notably through checkpoint inhibitors, has significantly reshaped cancer treatment over the past decade. Espen integrates clinical and research expertise as Director of Medical Affairs.

Treatment 122

Treatment Immune Response Vaccine Therapies 122

Drug Discovery World

MAY 8, 2024

The ORCA-V1 trial was led by Achieve Life Sciences, and co-led by an investigator from Massachusetts General Hospital. The ORCA-V1 trial was led by Achieve Life Sciences, and co-led by an investigator from Massachusetts General Hospital. For cytisinicline treatment compared to placebo, 31.8% versus 15.1%

Clinical Trials 182

Clinical Trials Compliance Trials Drugs 182

Drug Discovery World

AUGUST 20, 2024

The US Food and Drug Administration (FDA) has approved axatilimab-csfr (Niktimvo), a colony stimulating factor-1 receptor-blocking antibody, for the treatment of chronic graft-versus-host disease (cGVHD).

FDA Approval 147

FDA Approval FDA Disease Therapies 147

Drug Discovery World

DECEMBER 13, 2023

OSE Immunotherapeutics and Nantes University Hospital have revealed positive interim data analysis from the FIRsT Phase I/II study evaluating FR104/VEL-101 immunotherapy in renal transplants. The exploration of FR104/VEL-101’s safety profile seems promising and encourages moving to a Phase II trial.”

Clinical Trials 130

Clinical Trials Hospitals Trials Clinical Development 130